Clinical trials: Gastrointestinal Stromal Tumors (GISTs)
Asian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With Imatinib
A Retrospective Study of C-kit Mutation Status in Asian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With Imatinib.
Imatinib is the current standard treatment for advanced GIST. Previous studies have shown that GIST genotype was associated with treatment outcomes with exon 11 having superior outcome compared with exon 9 or WT.10, 11 In…
- Trial name
- NCT01227746
- Testing
- Tumor biopsies
- Where
- Singapore
- Sponsor
- National University Hospital, Singapore
Gastrointestinal Stromal Tumors (GISTs)
To Explore the Optimal Therapeutic Window for Imatinib in the Adjuvant Treatment of Intermediate and High-risk Gastrointestinal Stromal Tumors
The goal of this observational study is to explore the quantitative relationship between in vivo exposure and efficacy, and the relationship between in vivo exposure and the risk of adverse reactions after adjuvant treatment of…
- Trial name
- NCT07614841
- Volunteers
- 328 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in…
- Conditions
- Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC
- Trial name
- NCT03114319
- Testing
- TNO155, TNO155 in combination with EGF816 (nazartinib)
- Where
- 18 sites in United States, Canada and 7 more
- Volunteers
- 227 people
- Sponsor
- Novartis Pharmaceuticals
Gastrointestinal Stromal Tumors
SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)
This study evaluates the combination of trametinib and pazopanib in patients with advanced gastrointestinal stromal tumors (GIST).
- Trial name
- NCT02342600
- Testing
- Pazopanib, Trametinib
- Sponsor
- Sarcoma Alliance for Research through Collaboration
GIST of Stomach, Gastric Cancer
Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site
Participants with gastrointestinal stromal tumors(GIST) were divided into favorable and unfavorable sites according to the anatomical site of the tumor, and this study aims to validate the overall postoperative morbidity and…
- Conditions
- GIST of Stomach, Gastric Cancer, Surgery, Complication
- Trial name
- NCT03716089
- Testing
- Laparoscopic resection
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Fujian Medical University
Gastro-Intestinal Stromal Tumour
Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence
The objective is to compare the efficacy and safety of masitinib at 4.5 mg/kg/day to placebo in the treatment of patients with localized, primary gastrointestinal stromal tumor (GIST) after complete surgery and with high risk of…
- Trial name
- NCT02009423
- Testing
- Masitinib
- Volunteers
- 7 people
- Sponsor
- AB Science
Gastrointestinal Stromal Tumors
Sorafenib for Imatinib/Sunitinib-failed GIST
With discovery of KIT (CD117) mutations and the advent of KIT tyrosine kinase inhibitor imatinib, there has been substantial improvement in overall survival in patients with advanced and/or metastatic gastrointestinal tumors…
- Trial name
- NCT01091207
- Testing
- Sorafenib
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Samsung Medical Center
GIST
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with…
- Trial name
- NCT03465722
- Testing
- avapritinib, regorafenib
- Where
- 114 sites in United States, Australia and 16 more
- Volunteers
- 476 people
- Sponsor
- Blueprint Medicines Corporation
Gastric GIST
Endoscopic Full Thickness Resection for Gastric GIST
This is a clinical trial to evaluate the efficacy and safety of endoscopic full thickness resection for treatment of gastric GIST
- Trial name
- EFTR (NCT04198337)
- Testing
- Endoscopic Full Thickness Resection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese University of Hong Kong
Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas
Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)
The primary objectives of the study are: Determine the safety and maximum tolerated dose (MTD) of IPI-504 in GIST and STS patients who have failed prior therapies Recommend a dose for subsequent studies of IPI-504
- Trial name
- NCT00276302
- Testing
- IPI-504
- Where
- 5 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Gastrointestinal Stromal Tumor
Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index
Following the ACOSOG Z9001trial, imatinib received market authorization in Europe for patients with GIST at significant risk of relapse in the adjuvant setting, according to the classifications of Miettinen and Joensuu.
- Trial name
- GIGIST (NCT02576080)
- Testing
- Imatinib, Surveillance
- Volunteers
- 80 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor
Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
This is a multicenter, interventional, randomized study among adult patients recently diagnosed with a rare tumor (<12 months). The study will aim to compare compliance with the personalized post-treatment surveillance plan…
- Conditions
- Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor, Gastrointestinal Stromal Tumors, Ovarian Germ Cell Tumor
- Trial name
- SUR-CAN (NCT05500391)
- Testing
- Oncological Follow-up
- Where
- 3 sites in France
- Volunteers
- 88 people
- Sponsor
- Centre Oscar Lambret
Gastrointestinal Stromal Tumor, Major Gastrectomy
Influence of an Acidic Beverage on the Imatinib Exposure After Major Gastrectomy
The most common sites for GIST to occur are the stomach (60-70%) and proximal small intestines (20-25%). Therefore patients with GIST often have altered GI-tract due to tumor resection or palliative surgery which might affect…
- Trial name
- ABILITY (NCT02185937)
- Testing
- cola
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Radboud University Medical Center
Gastrointestinal Stromal Tumors
A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
The primary objective of this trial is to evaluate the progress free survival (PFS) of DCC-2618 in patients with advanced gastrointestinal stromal tumors who have progressed with prior anticancer therapies based on independent…
- Trial name
- NCT04282980
- Testing
- DCC-2618
- Where
- 9 sites in China
- Volunteers
- 39 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma, Malignant Gastrointestinal Stromal Tumor
Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Advanced/Metastatic Malignant GIST
Study Design Type of Study This is an open-label, single arm, prospective, multiple-center phase II study Duration of the Study Period in One Subject Treatment duration is planned for six cycles, unless there is evidence of…
- Trial name
- STS (NCT00359333)
- Testing
- Gemcitabine , Docetaxel
- Where
- Taiwan
- Volunteers
- 58 people
- Sponsor
- National Health Research Institutes, Taiwan
Gastrointestinal Stromal Tumors
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
The purpose of this study is to determine if escalating the dose of imatinib to keep the drug blood level at ≥ 1100 ng/ml leads to better outcomes for patients.
- Trial name
- NCT01031628
- Testing
- Imatinib mesylate
- Where
- 13 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Gastro Intestinal Stromal Tumour
Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure
The primary objective is to compare the efficacy of lenvatinib plus Best Supportive Care versus Placebo plus Best Supportive Care in the treatment of patients with advanced GIST, after failure of imatinib and sunitinib.
- Trial name
- LENVAGIST (NCT04193553)
- Testing
- Lenvatinib, Best supportive care
- Where
- 14 sites in France
- Volunteers
- 77 people
- Sponsor
- Centre Leon Berard
Gastrointestinal Stromal Tumor
Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known which dose of imatinib mesylate is more effective in treating gastrointestinal stromal…
- Trial name
- NCT00685828
- Testing
- imatinib mesylate
- Volunteers
- 946 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC